DNA strands protecting healthy skin cells

Decoding TERT Promoter Mutations: Are You at Risk for Skin Cancer?

Soraya Malik monogram
Soraya Malik in Health & Wellness October 2026 • 5 min read.

"Unlocking the Secrets of TERT Mutations for Early Prognosis and Personalized Treatment Strategies in Cutaneous Oncology"


Dermatologists face the critical task of accurately predicting the course of skin cancers to ensure patients receive the most effective care. This is especially challenging in cases of borderline or recurrent lesions, where traditional methods may fall short. However, as molecular techniques in diagnostic dermatopathology become more advanced, understanding which tools offer the greatest value is essential.

In the ever-evolving landscape of cancer research, telomeres and telomerase have emerged as key players in aging and cancer development. Telomeres, found at the ends of eukaryotic chromosomes, safeguard our genetic information. Telomerase reverse transcriptase (TERT) is an enzyme responsible for maintaining telomere length, and its activity is crucial for cell division. Understanding how TERT promoter mutations impact cancer prognosis is a new, emerging field of medicine.

This article explores the significance of TERT promoter mutations in cutaneous oncology, drawing from recent studies published in the Journal of the American Academy of Dermatology. We'll delve into how these mutations can serve as prognostic markers, potentially leading to earlier detection, personalized treatment strategies, and improved outcomes for those at risk.

AI Search Multiple angles on this topic

TERT Mutations and Melanoma Outcomes

TERT promoter mutations are frequent in melanoma and have been identified in cutaneous melanoma tumor samples and cell lines. A 2021 systematic review and meta-analysis pooled data from nineteen independent studies involving more than 2,500 melanoma cases to examine their association with survival. Research has also assessed progression-free survival and overall survival, including relationships with BRAF genotyping.

What TERT Testing Can and Cannot Show

Studies commonly examine TERT promoter molecular status in paired primary melanoma and metastasis samples and evaluate its relationship with gene expression, disease aggressiveness, and prognosis. TERT promoter mutations can create binding sites for E-twenty-six family transcription factors, increasing telomerase expression and supporting telomere stability. However, the available research focuses on associations and prognostic interpretation, so TERT status alone does not establish a complete clinical picture.

TERT Promoter Mutations: A New Frontier in Skin Cancer Prognosis

DNA strands protecting healthy skin cells

Telomeres and telomerase have long been recognized for their roles in aging and cancer. Telomeres, protective caps at the ends of our chromosomes, shorten with each cell division. In normal cells, this shortening triggers senescence, limiting cell growth. However, in cancer cells, telomerase can maintain telomere length, allowing unlimited proliferation and contributing to tumor development.

TERT promoter mutations (TPMs) have been identified in various cancers, including melanoma, glioma, and hepatocellular carcinoma. These mutations are often associated with adverse outcomes, making them potential biomarkers for predicting disease progression. Notably, TPMs are among the most common non-coding mutations in human cancer, sparking debate about whether cancer originates from telomerase-positive stem cells or if telomerase reactivation is a late-stage event in cellular transformation.

  • TPMs in Cutaneous Squamous Cell Carcinoma (cSCC): A study by Campos et al. investigated TPMs in a retrospective series of cSCC cases. The research revealed that the mutation rate was 31.6%, with a higher prevalence in invasive tumors (34.7%) compared to in situ tumors (19.4%). Older patients were found to have independent predictor of local reoccurance.
  • TPMs in Recurrent Nevi and Melanoma: Walton et al. explored the role of TPMs in distinguishing recurrent nevi from recurrent melanoma. The study found that hotspot TPMs were significantly more frequent in recurrent melanomas, suggesting their potential as a diagnostic clue in ambiguous cases.
AI Search Multiple angles on this topic

Limits of Prognostic Certainty

TERT promoter alterations were among the most prevalent aberrations in one reported cancer population, occurring in 56% of patients with melanoma and 48% of patients with brain cancers. However, the source notes that only a higher number of alterations remained significant in multivariate analysis, showing that individual molecular findings may not retain independent significance after adjustment. A separate report describes TERT promoter mutations as potential predictors of poor prognosis in cutaneous squamous cell carcinoma, but the supplied material does not provide its specific prognostic results.

Patterns Across Melanoma

TERT promoter mutations are reported as frequent in both chronic and non-chronic sun-damage melanoma. They correlate with adverse prognosis and may inform melanoma pathogenesis and management. Research has also compared TERT mutation status and TERT protein expression in large melanoma series, as well as associations with progression-free and overall survival according to BRAF genotype.

While the desire for a single test to definitively determine whether a lesion is benign or malignant is strong, the reality is more complex. Accurate diagnosis relies on clinical-pathologic correlation, integrating routine microscopy with advanced techniques like immunohistochemistry and molecular tests. However, preliminary data suggest that TPMs may emerge as valuable tools in cutaneous oncology prognostication, pending further research.

The Future of Skin Cancer Diagnosis: Personalized Approaches and Early Detection

The discovery of TERT promoter mutations has opened new avenues for understanding and managing skin cancer. By identifying these mutations, clinicians can potentially predict the aggressiveness of tumors and tailor treatment strategies accordingly. This personalized approach holds the promise of improving outcomes and quality of life for patients.

AI Search Multiple angles on this topic

Toward More Precise Risk Prediction

Recent data suggest that different TERT promoter mutations may have different effects on prognosis rather than sharing one uniform risk profile. A 2025 report specifically examined the prognostic significance of TERT promoter mutation loci, including C250T mutations, in melanoma. Broader discussion of TERT promoter mutations emphasizes their potential to support earlier detection, personalized treatment, and improved outcomes, although these applications remain an evolving area of research.

Early detection remains crucial in the fight against skin cancer. Regular self-exams, professional screenings, and awareness of risk factors are essential. If you notice any suspicious moles or lesions, consult a dermatologist promptly. Early intervention can significantly increase the chances of successful treatment.

As research continues to unravel the complexities of TERT promoter mutations, we can expect further advancements in skin cancer diagnostics and therapeutics. Staying informed about the latest findings and working closely with healthcare professionals are key steps in protecting your skin health and ensuring the best possible outcomes.

Melanoma survival findings against wild-type tumors

  • 1.52 and 1.77When overall and melanoma-specific survival estimates were combined, the summary estimate was 1.52 (95% CI 1.14–2.02); among studies mostly involving invasive non-acral cutaneous melanoma, it was 1.77 (95% CI 1.00–3.15).[1]
  • 68%, 64%, and 24% percentIn matched primary melanoma and metastasis samples, mutations were reported in 68% of primary tumors and 64% of metastases, while mutation status differed between the paired sites in 24% of cases.[2]

What the TERT findings add up to

The survival estimates point in the same direction: mutated melanoma groups had poorer survival than comparison groups. They describe an association, not proof that mutation status by itself determines an individual's outcome.[1]

How the findings compare across cancer settings

Evidence for melanoma survival extends beyond overall survival: the review describes limited but suggestive detrimental associations with disease-free and distant metastasis-free survival as well.[1]

In melanoma cohorts receiving immune checkpoint inhibition, multivariate analyses did not show a consistent survival association for TERT promoter mutations or TERT expression. That result differs in scope from the pooled survival comparisons and cautions against treating the association as uniform across settings.[1] [3]

For melanoma treated with MAPK inhibitors, the cited prognostic context includes disease stage, baseline LDH, brain metastases, and baseline ECOG performance status. These are clinical factors considered alongside molecular findings, rather than evidence that TERT status alone captures prognosis.[4]

What remains unresolved about TERT and prognosis

  • How consistently do TERT promoter mutations relate to survival measures beyond overall and melanoma-specific survival, given that evidence for other measures is described as limited?[1]

Sources

  1. TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis. (pubmed.ncbi.nlm.nih.gov)
  2. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma (pmc.ncbi.nlm.nih.gov)
  3. TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities (pmc.ncbi.nlm.nih.gov)
  4. TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1016/j.jaad.2018.12.039, Alternate LINK

Title: Promoting Tert Promoter Mutations For Prognostication In Cutaneous Oncology

Subject: Dermatology

Journal: Journal of the American Academy of Dermatology

Publisher: Elsevier BV

Authors: Warren R. Heymann

Published: 2019-03-01

Everything You Need To Know

1

What are telomeres and what is their role in cancer development?

Telomeres are protective caps at the ends of chromosomes, crucial for safeguarding genetic information. They naturally shorten with each cell division, which in normal cells, leads to senescence, limiting cell growth. In contrast, cancer cells may maintain telomere length through telomerase, which allows for unlimited proliferation and contributes to tumor development.

2

What are TERT promoter mutations (TPMs)?

TERT promoter mutations (TPMs) are alterations in the promoter region of the telomerase reverse transcriptase (TERT) gene. This gene encodes the enzyme telomerase, which is responsible for maintaining telomere length. The presence of TPMs can influence a tumor's ability to proliferate indefinitely. TPMs are frequently found in various cancers, including melanoma and cutaneous squamous cell carcinoma (cSCC), and are associated with a poorer prognosis, making them valuable biomarkers. Studies have shown that TPMs are significantly more frequent in recurrent melanomas, which indicates their importance in diagnosis.

3

Why are TERT promoter mutations (TPMs) significant in skin cancer?

TPMs are significant because they can be used as prognostic markers in skin cancer, potentially allowing for earlier detection and more personalized treatment strategies. The identification of TPMs can help clinicians predict the aggressiveness of tumors. For example, in cutaneous squamous cell carcinoma (cSCC), a study by Campos et al. found that TPMs were associated with a higher prevalence in invasive tumors compared to in situ tumors. In recurrent nevi and melanoma, studies have shown that TPMs are significantly more frequent in recurrent melanomas, suggesting their importance as a diagnostic tool in ambiguous cases.

4

Why is early detection of TERT promoter mutations important?

Early detection of skin cancer through the identification of TERT promoter mutations is important because it allows for more effective, personalized treatments and potentially improves outcomes. Clinicians can use the information to predict the aggressiveness of tumors, which allows the tailoring of treatment strategies to individual patients. This approach can lead to better management and improved quality of life for patients. The identification of TPMs is also crucial in distinguishing recurrent nevi from recurrent melanoma, particularly in ambiguous cases.

5

How can the discovery of TERT promoter mutations lead to personalized treatment strategies for skin cancer?

Personalized treatment strategies involve tailoring medical treatments to individual patients based on their specific characteristics and the unique features of their cancer. The discovery of TERT promoter mutations opens new avenues for managing skin cancer by identifying these mutations and predicting the aggressiveness of tumors. This approach is a paradigm shift from the traditional, one-size-fits-all approach, leading to a more targeted and effective management of skin cancer. For example, clinicians can use this information to tailor treatment strategies accordingly. This is essential for improving outcomes and quality of life for patients.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.